Differential expression of fatty acid synthase (FAS) and ErbB2 in nonmalignant and malignant oral keratinocytes
✍ Scribed by Sabrina D. Silva; Isabela W. Cunha; Ana Lúcia C. A. Rangel; Jacks Jorge; Karina G. Zecchin; Michelle Agostini; Luiz P. Kowalski; Ricardo D. Coletta; Edgard Graner
- Book ID
- 106117975
- Publisher
- Springer
- Year
- 2008
- Tongue
- English
- Weight
- 728 KB
- Volume
- 453
- Category
- Article
- ISSN
- 1432-2307
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Background. Fatty acid synthase (FASE) is required for fatty acid synthesis. Elevated levels of FASE have been observed in a variety of malignancies. Methods: We examined the expression of FASE in 56 primary squamous cell carcinomas (SCC) of the tongue using immunohistochemistry (IHC) with a monocl
## BACKGROUND. Fatty acid synthase (FAS) is a molecule found in tumor cells from breast carcinomas of patients whose prognosis is very poor. Recently, this molecule has been identified as the key enzyme in fatty acid biosynthesis. This study was done to test the strength of FAS as a prognostic ind
## Abstract Relatively little information exists on the ultimate molecular mechanisms by which the lipogenic enzyme Fatty Acid Synthase (FAS) is differentially overexpressed in a biologically aggressive subset of human malignancies. Since the microenvironment of solid tumors contains regions of poo
## Abstract ## Background Treatment of nephroblastoma (Wilms tumor) has presently achieved a greater than 80% cure rate. Pathologic stage and grade are considered the most reliable prognostic parameters, but other biologic factors are under study in order to improve patient stratification into ris